B-cell Malignancy clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

    open to eligible people ages 18 years and up

    This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

    Orange 5379513, California 5332921 and other locations

Our lead scientists for B-cell Malignancy research studies include .

Last updated: